British Society for Rheumatology publishes updated guideline non-biologic disease modifying anti-rheumatic drugs (DMARDs).
This latest guidance sets out evidence based recommendations for clinicians prescribing synthetic, non-biologic, anti-rheumatic drugs to tackle multisystem rheumatic conditions. Previous guidelines on DMARDs were published in 2008 but significant shifts in the evidence base mean updated guidance is needed. Monitoring of DMARDs is essential and the guideline includes focuses on baseline screening; implications of co-morbid illness; monitoring for toxicity; management during intercurrent illness or surgery, and shared care guidance.…
Read more of this article